AstraZeneca Acquires Fusion Pharmaceuticals in $2.4B Nuclear Medicine Deal

Mar 19, 2024 20:39 CST Updated 20:39

Fusion Pharmaceuticals

Biopharmaceutical R&D and Manufacturing

AstraZeneca

Biopharmaceutical Manufacturer

Who is the next "sell-out" nuclear medicine Biotech? Which MNC will be the next to make a bold move? The answer has arrived.

On March 19, Fusion Pharmaceuticals, a leading radiopharmaceutical company, officially announced its acquisition by AstraZeneca. According to the terms of the final agreement, AstraZeneca will acquire all outstanding shares of Fusion through a subsidiary, with the cash portion of the transaction valued at approximately $2 billion.The total transaction value, including upfront and maximum potential or valuable payments, amounts to approximately $2.4 billion (RMB 17 billion).Affected by this news, Fusion Pharmaceuticals, Inc. surged more than 90% in pre-market trading.

Notably, when the nuclear medicine sector regained momentum in the past two years,In recent years, many MNCs that were previously in a wait-and-see position have begun to take action, among whichAstraZeneca was the first to step in, but its previous participation was mostly in the form of small-scale cooperative development. However, it is obvious that this bold acquisition demonstrates its determination to strengthen its position.

Nuclear medicine has become a popular field for many MNCs to invest in.By the end of 2022, nuclear medicine was still an important competitive advantage for the two multinational corporations, Novartis and Bayer, butIn just one year, 2023, at least five MNCs have aggressively entered the market and are making a strong push.Lilly and BMS Take the Lead with High-Premium Acquisitions of Star Targets; AstraZeneca, Johnson & Johnson, and Merck Also Secure at Least One Nuclear Medicine Product or Platform through Collaboration, BD, and Other Means.

On the other hand, as E Pharm Manager predicted,The survival path for nuclear medicine Biotech companies is likely limited to two options: either being acquired or out-licensing their products through business development (BD).

The field of nuclear medicine is unique in that only those with substantial capabilities can enter. Without a technological platform, ligand discovery ability, and CMC experience, participation is out of the question. Those who succeed almost always secure substantial financing. However, as nuclear medicine gains popularity, the exclusive path for Biotech firms and their strong ties with large pharmaceutical companies become increasingly evident: the "inner circle" consists of a few established/large pharmaceutical companies that can connect to or control nuclear medicine industry resources, while the "outer circle" comprises a small number of Biotech firms. These firms push potential products to the mid-to-late clinical stages but often lack the funds and resources to scale up production capacity, ensure quality, and manage transportation. Consequently, nearly all outer-circle players opt to strike BD deals with inner-circle pharmaceutical companies or be acquired by them.

Fusion (founded in 2014) has consistently been a favored radiopharmaceutical target for AstraZeneca, Merck, and Johnson & Johnson, holding the differentiated technology platform Fast-Clear linker, with R&D progress ranking relatively high among similar companies and its technology being quite mature.At the same time, the target layout of Fusion is different from the two mainstreams of PSMA and SSTR. Its feature is to use α nuclides to develop radiopharmaceuticals targeting α rays.

With certain technical features, Fusion currently holds the core product FPI-2265 (Phase II clinical trial) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Previously,FusIon prediction,FPI-2265 has a potential market opportunity of at least approximately 1 billion US dollars.

However, it is worth mentioning that α-rays do indeed have higher potency and a shorter range, exhibiting significant cytotoxic effects within a limited area of the target. But α-emitters still face the major issue of stimulated decay, and they are extremely unstable in the body, potentially causing severe side effects in certain organs. This challenge remains unsolved internationally to this day, posing risks of failure in development. In May 2023, Fusion Pharmaceuticals decided to halt the development of FPI-1966, its targeted alpha therapy that had been under research for approximately three years, to focus its resources and funding solely on the most advanced product in its pipeline.

Aside from the risk of R&D investment potentially going to waste, the budget for Biotech companies to independently drive the entire process of radiopharmaceutical R&D and commercialization is far more complex and challenging than imagined. Manufacturing, logistics and transportation capabilities, as well as the ability to establish production facilities globally in a decentralized manner, are unavoidable difficulties and tests for radiopharmaceutical Biotechs.Considering various factors, the productHanding over to large pharmaceutical companies, or directly "selling out," seems to be a more realistic way out for nuclear medicine biotechs.

Now, several major star companies in the nuclear medicine field have been successively acquired by MNCs. Who will be the next?